Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 10/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29945392 | 1.00 | AURKA (0.51) | AURKAPARP1TRPA1CD44HSD17B10 | |
| Hydrochloric Acid SCHEMBL30040239 | 0.98 | AURKA (0.50) | AURKAPARP1TRPA1CD44HSD17B10 | |
| SCHEMBL8206404 | 0.85 | BCAT2 (0.46) | AURKAPARP1TRPA1HSD17B10ALOX15 | |
| SCHEMBL27901033 | 0.84 | CD44 (0.57) | AURKAPARP1TRPA1CD44HSD17B10 | |
| SCHEMBL29800858 | 0.84 | PNMT (0.53) | AURKAPARP1CD44PARP2 | |
| SCHEMBL30314450 | 0.84 | CD44 (0.57) | AURKAPARP1TRPA1CD44HSD17B10 | |
| SCHEMBL15569496 | 0.84 | PNMT (0.53) | AURKAPARP1CD44PARP2 | |
| SCHEMBL1817879 | 0.83 | ALDH1A1 (0.43) | AURKATRPA1CD44HSD17B10ALOX15 | |
| SCHEMBL29662964 | 0.83 | ALDH1A1 (0.43) | AURKATRPA1CD44HSD17B10ALOX15 | |
| Hydrochloric Acid SCHEMBL2494227 | 0.83 | PNMT (0.51) | AURKAPARP1CD44PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| WO-2017158388-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
| EP-2454237-A1 | 3-0X0-2, 3, -DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES WITH SELECTIVE PARP-1 INHIBITION | Nerviano Medical Sciences S.r.l. (IT) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011006803-A8 | 3-0X0-2, 3, -DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES WITH SELECTIVE PARP-1 INHIBITION | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-03-17 | — | — | WO | disclosed |
| WO-2011006803-A1 | 3-0X0-2, 3, -DIHYDRO-LH-ISOINDOLE-4-CARBOXAMIDES WITH SELECTIVE PARP-1 INHIBITION | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | AURKA 869/4885PARP1 1051/4885TRPA1 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.